Alaunos Therapeutics Statistics
Total Valuation
TCRT has a market cap or net worth of $3.41 million. The enterprise value is $1.73 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, before market open.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TCRT has 1.60 million shares outstanding. The number of shares has increased by 1.88% in one year.
| Current Share Class | 1.60M |
| Shares Outstanding | 1.60M |
| Shares Change (YoY) | +1.88% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 3.60% |
| Owned by Institutions (%) | 8.66% |
| Float | 1.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.25 |
| P/TBV Ratio | 1.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 246.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.30
| Current Ratio | 4.30 |
| Quick Ratio | 2.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -141.72% and return on invested capital (ROIC) is -52.10%.
| Return on Equity (ROE) | -141.72% |
| Return on Assets (ROA) | -40.33% |
| Return on Capital (ROIC) | -52.10% |
| Revenue Per Employee | $7,000 |
| Profits Per Employee | -$11.78M |
| Employee Count | 1 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.93% in the last 52 weeks. The beta is -0.50, so TCRT's price volatility has been lower than the market average.
| Beta (5Y) | -0.50 |
| 52-Week Price Change | -78.93% |
| 50-Day Moving Average | 2.45 |
| 200-Day Moving Average | 8.73 |
| Relative Strength Index (RSI) | 46.11 |
| Average Volume (20 Days) | 15,929 |
Short Selling Information
The latest short interest is 139,306, so 8.70% of the outstanding shares have been sold short.
| Short Interest | 139,306 |
| Short Previous Month | 132,342 |
| Short % of Shares Out | 8.70% |
| Short % of Float | 10.65% |
| Short Ratio (days to cover) | 10.12 |
Income Statement
In the last 12 months, TCRT had revenue of $7,000 and -$11.78 million in losses. Loss per share was -$7.39.
| Revenue | 7,000 |
| Gross Profit | -16.27M |
| Operating Income | -7.42M |
| Pretax Income | -26.77M |
| Net Income | -11.78M |
| EBITDA | -7.17M |
| EBIT | -7.42M |
| Loss Per Share | -$7.39 |
Full Income StatementBalance Sheet
| Cash & Cash Equivalents | 1.68M |
| Total Debt | n/a |
| Net Cash | 1.68M |
| Net Cash Per Share | $1.05 |
| Equity (Book Value) | 2.72M |
| Book Value Per Share | 1.70 |
| Working Capital | 2.72M |
Full Balance SheetCash Flow
| Operating Cash Flow | -11.76M |
| Capital Expenditures | n/a |
| Free Cash Flow | -11.76M |
| FCF Per Share | -$7.35 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -105,957.14% |
| Pretax Margin | -168,285.71% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -426,180.00% |